Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy, as determined by medical history, clinical examination, and biological safety parameters.~* Aged 18 to 45 years on the day of inclusion.~* Provision of informed consent signed by the participant or another legally acceptable representative.~* For a woman of child-bearing potential, use of an effective method of contraception or abstinence for at least 4 weeks prior to the first vaccination, and until at least 4 weeks after the last study vaccination.~* Able to attend all scheduled visits and to comply with all trial procedures.~Exclusion Criteria:~* Personal or family history of thymic pathology (thymoma), thymectomy, or myasthenia.~* For a woman of child-bearing potential, known or suspected pregnancy or positive serum/urine pregnancy test.~* Breast-feeding woman.~* Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination.~* Planned participation in another clinical trial during the present trial period.~* Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term (at least 2 weeks within the previous 3 months) systemic corticosteroids therapy (at a dose of at least 10 mg). Topical steroids were allowed.~* Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances.~* Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the investigator.~* Current or past alcohol abuse or drug addiction that may interfere with the participant's ability to comply with trial procedures.~* Receipt of blood or blood-derived products in the past 3 months, that might interfere with the assessment of immune response.~* Receipt of any vaccine in the 4 weeks preceding the first trial vaccination.~* Planned receipt of any vaccine in the 4 weeks following each of the trial vaccinations.~* Human Immunodeficiency Virus (HIV), hepatitis B surface antigen, or hepatitis C virus seropositivity in blood sample taken at Screening.~* Participant deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent.~* Clinically significant laboratory test abnormalities (as determined by the investigator) in blood sample taken at Screening.~* Previous residence in, travel or planned travel of more than 2 weeks during the study period to areas with high dengue infection endemicity.~* Reported history of flavivirus infection as reported by the participant.~* Previous vaccination against flavivirus diseases (including Japanese encephalitis, tick-borne encephalitis, and yellow fever).~* Flavivirus vaccination planned during the trial period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- CYD Dengue Vaccine 5555 Formulation (Type: EXPERIMENTAL): Participants received 3 doses of CYD dengue vaccine (5555 formulation); one each at 0 (vaccination 1), 6 (vaccination 2), and 12 (vaccination 3) months.
- CYD Dengue Vaccine 5553 Formulation (Type: EXPERIMENTAL): Participants received 3 doses of CYD dengue vaccine (5553 formulation); one each at 0 (vaccination 1), 6 (vaccination 2), and 12 (vaccination 3) months.
- CYD Dengue Vaccine 4444 Formulation (Type: EXPERIMENTAL): Participants received 3 doses of CYD dengue vaccine (4444 formulation); one each at 0 (vaccination 1), 6 (vaccination 2), and 12 (vaccination 3) months.

Based on this trial design, predict the completion outcome and termination type (if applicable).